Upstream Bio, Inc. Common Stock
Symbol: UPB (NASDAQ)
19.85
▲ (0.30%) 0.060
Company Description:
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Key Stats
- Today's Open: $19.8
- Today's High: $20.675
- Today's Low: $19.35
- Today's Volume: 271.81K
- Yesterday Close: $19.79
- Yesterday High: $20.09
- Yesterday Low: $18.61
- Yesterday Volume: 636.39K
- Last Min Volume: 31
- Last Min High: $19.85
- Last Min Low: $19.85
- Last Min VWAP: $19.85
Company Profile
- Name: Upstream Bio, Inc. Common Stock
- Website: https://www.upstreambio.com
- Listed Date: 2024-10-11
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0002022626
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.06B
- Round Lot: 100
- Outstanding Shares: 53.91M
- Asset Type: CS
RECENT FILINGS FOR UPB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-02 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-06-12 | 8-K | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-05-06 | 10-Q | View |
| 2025-05-06 | 8-K | View |
| 2025-04-17 | ARS | View |
| 2025-04-17 | DEFA14A | View |
| 2025-04-17 | DEF 14A | View |
| 2025-03-12 | S-8 | View |
| 2025-03-12 | 10-K | View |
| 2025-03-12 | 8-K | View |
| 2025-02-14 | SCHEDULE 13G | View |
Latest News on UPB